Can Once Daily GLP-1 Lyxumia Be The Next Major Growth Driver For Sanofi?
- Lyxumia's fortune hinges on results from ELIXA, a cardiovascular outcome study to report data in early 2015.
- Currently consensus forecasts for Lyxumia do not assume a positive outcome from the ELIXA study.
- I believe there is a good chance that ELIXA will report positive data. In such a scenario the consensus estimates for Lyxumia will increase from $450m to $2.9b.